ClinicalTrials.gg
CompletedNCT03986138PROMISEUpdated Oct 27, 2025Results posted

Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI)

A Phase 3 interventional study of gadopiclenol and Gadobutrol 1 MMOLE/ML Intravenous Solution in Lesion in Body Region, sponsored by Guerbet. Completed at 33 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-27.

Sponsored by Guerbet · Phase 3, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
324
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The trial aimed at evaluating the efficacy and the safety of gadopiclenol for body Magnetic resonance Imaging (MRI)

Read the detailed description

The purpose of this trial was to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol in terms of lesion visualization in patients referred for contrast-enhanced MRI of body regions.

This is a prospective, international, multi-center, randomized, double-blind, controlled and cross-over trial.

This trial was conducted in 33 centers worldwide. During the course of the trial, two MRIs were obtained from each patient: one with gadopiclenol and one with gadobutrol. MRI evaluations were assessed by independent off-site blinded readers.

02

Conditions studied

  • Lesion in Body Region
03

In context

Lead sponsor

Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient presenting with known or suspected enhancing abnormality(ies) and/or lesion(s) in at least one body region based on a previous imaging procedure performed within 12 months prior to ICF signature. US patients are restricted to the breast in compliance with local approved indications of gadobutrol.

Exclusion criteria

Exclusion Criteria:

  • Patient presenting with acute or chronic renal insufficiency, defined as an estimated (eGFR) \< 30 mL/min/1.73 m² assessed within 1 day prior to each contrast agent administration.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
324 participants (actual)

Study arms

  • Experimental
    gadopiclenol-enhanced MRI then gadobutrol-enhanced MRI

    Cross-over design: each patient receives gadopiclenol for the first MRI and then gadobutrol for the second MRI

    Drug: gadopiclenol · Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution

  • Experimental
    gadobutrol-enhanced MRI then gadopiclenol-enhanced MRI

    Cross-over design: each patient receives gadobutrol for the first MRI and then gadopiclenol for the second MRI

    Drug: gadopiclenol · Drug: Gadobutrol 1 MMOLE/ML Intravenous Solution

Interventions

  • Single intravenous bolus injection

  • DrugGadobutrol 1 MMOLE/ML Intravenous Solution

    Single intravenous bolus injection

06

What researchers measure

Primary outcomes

  1. Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI

    The lesion visualization at patient level was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.

    Time frame: At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.

Secondary outcomes

  1. Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI

    The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.

    Time frame: At each of two MRI examinations with an interval of 2-14 days between two MRI examinations

07

Results

Posted Oct 27, 2025

Participant flow

First MRI Examination
Participant flow — First MRI Examination
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started152152
Completed151149
Not completed13
Withdrew: Physician decision01
Withdrew: Other reason (mainly technical issues with mri machine)12
Washout
Participant flow — Washout
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started151149
Completed141136
Not completed1013
Withdrew: Withdrawal by subject45
Withdrew: Lost to follow-up02
Withdrew: Adverse event11
Withdrew: Other reason55
Second MRI Examination
Participant flow — Second MRI Examination
MilestoneArm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRI
Started141136
Completed141134
Not completed02
Withdrew: Withdrawal by subject02

Outcome measures

PrimaryLesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI

The lesion visualization at patient level was based on 3 co-primary criteria on marching lesions: border delineation, internal morphology and degree of contrast enhancement, assessed on the images acquired during the MRI performed with gadopiclenol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each co-criterion was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between Paired \[unenhanced and contrast-enhanced\] images and Pre-contrast \[unenhanced\] images was calculated for each of the 3 co-primary criteria and for each reader.

Time frame:
At first MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 1. At second MRI examination (gadopiclenol-enhanced MRI) for patients of Arm 2, performed 2-14 days after gadobutrol-enhanced MRI.
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Unenhanced MRI
mean of a score (on a scale) per patientPatients With Gadopiclenol Paired ImagesPatients With Gadopiclenol Pre Images
Border delineation - Reader 13.79 ± 0.032.26 ± 0.03
Border delineation - Reader 23.48 ± 0.063.01 ± 0.06
Border delineation - Reader 33.49 ± 0.031.78 ± 0.03
Internal morphology - Reader 13.80 ± 0.021.99 ± 0.02
Internal morphology - Reader 23.75 ± 0.053.22 ± 0.05
Internal morphology - Reader 33.72 ± 0.031.69 ± 0.03
Contrast enhancement - Reader 13.64 ± 0.031.00 ± 0.03
Contrast enhancement - Reader 22.82 ± 0.051.00 ± 0.05
Contrast enhancement - Reader 33.33 ± 0.031.00 ± 0.03
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = < 0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.53 · 95% CI 1.46 to 1.60
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 0.47 · 95% CI 0.36 to 0.58
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.71 · 95% CI 1.65 to 1.78
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.81 · 95% CI 1.76 to 1.87
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 0.53 · 95% CI 0.42 to 0.64
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.03 · 95% CI 1.95 to 2.11
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.64 · 95% CI 2.56 to 2.72
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 1.82 · 95% CI 1.68 to 1.96
  • Patients With Gadopiclenol Paired Images vs Patients With Gadopiclenol Pre Images · t-test, 2 sided · p = <0.0001 (To demonstrate the superiority, a statistically significant (one-sided p-value ≤0.025) positive difference in mean scores in border delineation, internal morphology and degree of contrast enhancement of lesions had to be met for 2 out of 3 readers.) · Mean difference (final values): 2.33 · 95% CI 2.26 to 2.41
SecondaryLesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI

The lesion visualization (per patient) was based on 3 co-primary criteria: border delineation, internal morphology and degree of contrast enhancement, assessed on the images performed with gadopiclenol and images performed with gadobutrol by 3 independent readers. The independent blinded reader recorded each of the 3 co-primary criteria for up to 3 most representative lesions, using a 4-point scale (1 = poor \[internal morphology\] or none \[border delineation, contrast enhancement\], 2 = moderate, 3 = good, 4 = excellent). The mean of scores for each patient and for each of the 3 lesion visualization co-criteria was calculated as follows: Mean of scores = score of lesion 1 + score of lesion 2 (if any) + score of lesion 3 (if any) divided by the number of lesions, ranged from 1 to 4. The difference in mean scores on matching lesions between gadopiclenol scores mean and gadobutrol scores mean was calculated for each of the 3 co-primary criteria and for each reader.

Time frame:
At each of two MRI examinations with an interval of 2-14 days between two MRI examinations
Reported as:
Least squares mean · mean of a score (on a scale) per patient
Lesion Visualization Comparing Gadopiclenol-enhanced MRI to Gadobutrol-enhanced MRI
mean of a score (on a scale) per patientPatients With Gadopiclenol Paired ImagesPatients With Gadobutrol Paired Images
Border delineation - Reader 13.82 ± 0.023.81 ± 0.02
Border delineation - Reader 23.56 ± 0.053.53 ± 0.05
Border delineation - Reader 33.53 ± 0.033.57 ± 0.03
Internal morphology - Reader 13.83 ± 0.023.83 ± 0.02
Internal morphology - Reader 23.75 ± 0.043.75 ± 0.04
Internal morphology - Reader 33.74 ± 0.033.77 ± 0.03
Contrast enhancement - Reader 13.69 ± 0.043.68 ± 0.04
Contrast enhancement - Reader 22.88 ± 0.072.86 ± 0.07
Contrast enhancement - Reader 33.35 ± 0.043.37 ± 0.04
Statistical analysis
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 (The Null hypothesis was rejected if the 2-sided 95% Confidence Interval (CI) for the difference \[gadopiclenol scores mean - gadobutrol scores mean\] had its lower limit above -0.35.) · Mean difference (final values): 0.00 · 95% CI -0.05 to 0.05The Student's t-based 95% CIs of the difference between gadopiclenol and gadobutrol were constructed for each of 3 co-primary criteria.
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 (The Null hypothesis was rejected if the 2-sided 95% Confidence Interval (CI) for the difference \[gadopiclenol scores mean - gadobutrol scores mean\] had its lower limit above -0.35.) · Mean difference (final values): 0.02 · 95% CI -0.05 to 0.10The Student's t-based 95% CIs of the difference between gadopiclenol and gadobutrol were constructed for each of 3 co-primary criteria.
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 (The Null hypothesis was rejected if the 2-sided 95% Confidence Interval (CI) for the difference \[gadopiclenol scores mean - gadobutrol scores mean\] had its lower limit above -0.35.) · Mean difference (final values): -0.04 · 95% CI -0.10 to 0.01The Student's t-based 95% CIs of the difference between gadopiclenol and gadobutrol were constructed for each of 3 co-primary criteria.
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -0.0 · 95% CI -0.06 to 0.05
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -0.07 · 95% CI -0.07 to 0.07
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -0.03 · 95% CI -0.08 to 0.02
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.01 · 95% CI -0.06 to 0.09
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): 0.03 · 95% CI -0.07 to 0.12
  • Patients With Gadopiclenol Paired Images vs Patients With Gadobutrol Paired Images · t-test, 2 sided · p = <0.0001 · Mean difference (final values): -0.02 · 95% CI -0.08 to 0.04

Adverse events

Collected over Adverse events were recorded from informed consent signature up to one day after the second MRI (i.e., minimum of 4 days and a maximum of 23 days). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Gadopiclenol0/288 (0%)3/288 (1%)50/288 (17.4%)
Gadobutrol0/290 (0%)0/290 (0%)58/290 (20%)
Most frequent serious events
Most frequent serious events
EventGadopiclenolGadobutrol
Condition AggravatedGeneral disorders1/2880/290
Depressed Level Of ConsciousnessNervous system disorders1/2880/290
Covid-19Infections and infestations1/2880/290
Most frequent other events
Showing 10 of 74
Most frequent other events
EventGadopiclenolGadobutrol
HeadacheNervous system disorders16/2884/290
Injection site painGeneral disorders5/2887/290
NauseaGastrointestinal disorders5/2884/290
Incorrect dosage administeredInjury, poisoning and procedural complications5/2884/290
NeutropeniaBlood and lymphatic system disorders1/2884/290
Injection site bruisingGeneral disorders3/2881/290
Dry mouthGastrointestinal disorders3/2883/290
AnaemiaBlood and lymphatic system disorders2/2883/290
LeukopeniaBlood and lymphatic system disorders0/2883/290
ThrombocytopeniaBlood and lymphatic system disorders0/2883/290

Baseline characteristics

The analysis was based on participants. For the primary analysis to demonstrate the superiority of gadopiclenol-enhanced MRI compared to unenhanced MRI, the analysis population was patients who had both Pre (unenhanced) and Paired (combined unenhanced and contrast-enhanced) images with gadopiclenol assessable for primary criteria for at least one matching lesion for at least one off-site reader: 145 patients of Arm 1 who performed first MRI and 133 patients of Arm 2 who performed second MRI.

Age, Continuous
Age, Continuous(years)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Mean57.5 ± 12.956.9 ± 13.157.2 ± 13.0
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Female8282164
Male6351114
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Hispanic or Latino312051
Not Hispanic or Latino114113227
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
American Indian or Alaska Native181230
Asian222244
Native Hawaiian or Other Pacific Islander000
Black or African American246
White10294196
More than one race112
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
South Korea222244
Hungary282048
United States271845
Ukraine4913
Poland323567
Italy011
Mexico181230
France8210
Bulgaria2911
Germany235
Spain224
Weight
Weight(Kg)Arm 1: Gadopiclenol-enhanced MRI for First MRI and Gadobutrol-enhanced MRI for Second MRIArm 2: Gadobutrol-enhanced MRI for First MRI and Gadopiclenol-enhanced MRI for Second MRITotal
Mean75.3 ± 17.175.5 ± 17.175.4 ± 17.1
08

Study locations

33 sites
  • The University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • UConn Health - University of Connecticut
    Farmington, Connecticut 06030-2802, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • University of Missouri Health System
    Columbia, Missouri 65212, United States
  • Montefiore Medical Center
    The Bronx, New York 10467, United States
  • UT Health San Antonio
    San Antonio, Texas 78207, United States
  • Acibadem City Clinic Tokuda Hospital Sofia
    Sofia, Bulgaria
  • CHU
    Angers, France
  • CHU Beaujon
    Clichy, France
  • Hôpital Saint Louis
    Paris, France
  • Klinik für Diagnostische und Interventionelle Radiologie
    Aachen, Germany
  • Universitätsklinikum Halle
    Halle, Germany
  • Universitätsklinikum des Saarlandes
    Homburg, Germany
  • University Hospital Jena
    Jena, Germany
  • Somogy Megyei Kaposi Mor Oktato Korhaz
    Kaposvár, Hungary
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet
    Szolnok, Hungary
  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
    Naples, Italy
  • Clinical Research Institute S.C.
    Estado de México, Mexico
  • Axis Heilsa S de R.L. de C.V - Althian Clinical Research Management Center
    Monterrey, Mexico
  • Szpital Uniwersytecki Nr 1 im. dr Antoniego Jurasza w Bydgoszczy
    Bydgoszcz, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, Poland
  • Jagiellońskie Centrum Innowacji Sp. z o. o.
    Krakow, Poland
  • Szpital Świętego Rafała
    Krakow, Poland
  • Centrum Medyczne Affidea Wałbrzych
    Wałbrzych, Poland
  • Inje University Busan Paik Hospital
    Busan, South Korea
  • Bucheon Suncheonhyang Hospital
    Gyeonggi-do, South Korea
  • Korea University Anam Hospital
    Seoul, South Korea
  • Samsung Medical Center
    Seoul, South Korea
  • Seoul National University Hospital
    Seoul, South Korea
  • Hospital Universitario y Politécnico La Fe
    Valencia, Spain
  • St. Luke's Hospital
    Kropyvnytskyi, Ukraine
  • Borys Clinic
    Kyiv, Ukraine
09

References and documents

Publications

  • Kuhl C, Csoszi T, Piskorski W, Miszalski T, Lee JM, Otto PM. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology. 2023 Jul;308(1):e222612. doi: 10.1148/radiol.222612. PubMed 37462494 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2019 to primary completion in Dec 2020, 15 months.

Results were first posted in Oct 2025, 4 years 10 months after primary completion. A results delay was requested in May 2021.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2019
First posted
Jun 14, 2019
StartActual
Aug 27, 2019
Primary completionActual
Dec 9, 2020
CompletionActual
Dec 9, 2020
Results delay requested
May 12, 2021
Results first posted
Oct 27, 2025
Last update
Oct 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03986138
Lead sponsor
Guerbet
Responsible party
Sponsor
First posted
Jun 14, 2019
Start date
Aug 27, 2019
Primary completion
Dec 9, 2020
Completion
Dec 9, 2020
Results posted
Oct 27, 2025
Last update
Oct 27, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gadopiclenol

Start the discussion